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Monitoring the effect of first line treatment
in RAS/RAF mutated metastatic colorectal
cancer by serial analysis of tumor specific
DNA in plasma
C. B. Thomsen1,2* , T. F. Hansen1,2, R. F. Andersen1, J. Lindebjerg1,2, L. H. Jensen1,2 and A. Jakobsen1,2
Abstract
Background: Precision medicine calls for an early indicator of treatment efficiency. Circulating tumor DNA (ctDNA)
is a promising marker in this setting. Our prospective study explored the association between disease development
and change of ctDNA during first line chemotherapy in patients with RAS/RAF mutated metastatic colorectal cancer
(mCRC).
Methods: The study included 138 patients with mCRC receiving standard first line treatment. In patients with RAS/
RAF mutated tumor DNA the same mutation was quantified in the plasma using droplet digital PCR. The fractional
abundance of ctDNA was assessed in plasma before treatment start and at every treatment cycle until radiologically
defined progressive disease.
Results: RAS/RAF mutations were detected in the plasma from 77 patients. Twenty patients progressed on
treatment and 57 stopped treatment without progression. The presence of mutated DNA in plasma was correlated
with poor overall survival. A low level of ctDNA after the first cycle of chemotherapy was associated with a low risk
of progression. On the other hand, a significant increase of ctDNA at any time during the treatment course was
associated with a high risk of progression on continuous treatment. The first increase in ctDNA level occurred at a
median of 51 days before radiologically confirmed progression.
Conclusions: The results indicate that the ctDNA level holds potential as a clinically valuable marker in first line
treatment of mCRC. A rapid decrease was associated with a prolonged progression free interval, whereas a
significant increase gave notice of early progression with a relevant lead time.
Keywords: Circulating tumor DNA, RAS/RAF mutations, Metastatic colorectal cancer, Liquid biopsy, Monitoring,
Treatment efficiency
Background
Precision medicine is an important subject with growing
clinical interest in cancer treatment. The concept may
be complicated, but its core is as simple as “the right
treatment to the right patient at the right time”. The
issue has two aspects. Giving the right treatment is es-
sential, but discontinuing ineffective and potentially
toxic treatment holds the same importance and places
monitoring in a central position.
Easily accessible biomarkers validated for clinical
application are warranted. Blood samples have several
advantages over tissue biopsies and consequently, the
“liquid biopsy” concept has seen increased interest [1].
Tumor specific mutations in tissue rank high as tumor
markers of clinical relevance and are detectable by Next
Generation Sequencing (NGS). However a complete
characterization takes considerable resources and the
sensitivity is low, around 2% [2].
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In blood a promising approach is analysis of circulat-
ing tumor DNA (ctDNA) by droplet digital PCR
(ddPCR) with a high sensitivity (> 0.01%).
RAS/RAF mutations occur in 50–60% of colorectal can-
cer (CRC) patients [3, 4] and predict resistance to EGFR-
inhibiting antibodies. In the clinic the mutation analysis
thus serves as a tool for selection of targeted treatment.
New data show that ctDNA may replace tumor tissue ana-
lysis [5–8], and serial analysis may provide information as
to the relation of ctDNA with treatment effect and pro-
gression [9]. There are few studies in solid tumors dealing
with this issue. A proof of concept study has indicated that
fluctuations in the ctDNA level reflect changes of tumor
size in metastatic breast cancer [10]. A recent study has
looked at mutational dynamics during anti-EGFR therapy
[11], but there are no studies dealing with prediction of
progression in CRC during a treatment course.
The aim of the present study was to investigate the
possible value of ctDNA monitoring during chemother-
apy with respect to efficiency of first line treatment of
metastatic CRC (mCRC).
Methods
Study population
Patients with mCRC receiving first line treatment were
offered inclusion in a prospective biomarker study at
Danish Colorectal Cancer Center South, Vejle Hospital,
Denmark. The inclusion criteria are listed in the supple-
mentary material. Plasma samples from all patients were
collected at baseline and before every treatment cycle
throughout the treatment course. Treatment effect was
evaluated at every third cycle according to the RECIST
criteria blinded of mutational status.
The study was approved by The Regional Committees
on Health Research Ethics for Southern Denmark (S-
20100005) and the investigation was conducted in ac-
cordance with the REMARK criteria [12].
Tumor analysis
DdPCR (Bio-Rad®, Hercules, CA, USA) was used for the
analysis of all mutations in both tissue and plasma as de-
scribed below. The mutations were selected by combin-
ing the results from two previous studies [13, 14]. The
analyses were performed in three consecutive rounds
(Additional file 1: Table S1) as previously described [15]
and are further described in Additional file 2: Supple-
mentary material.
Blood sample analysis
Patients with RAS/RAF mutated DNA in the tumor
were selected for plasma analysis. We investigated the
26 most frequent KRAS and NRAS mutations in CRC
and the most frequent RAF mutation, BRAF V600E, as
further described in the supplementary material
(Additional file 3: Table S2) [13, 14]. The blood sampled
at each cycle of treatment was analyzed for the specific
mutation detected in the tumor tissue. A detailed de-
scription of the blood sample analysis and the ddPCR
can be found in Additional file 2: Supplementary
material.
We have recently published a method allowing for
screening with subsequent quantitative analysis of 27
RAS/RAF mutations in the blood [16]. This method was
applied in the screening of RAS/RAF mutations at time
of progression in patients with a wild-type tumor.
The specific mutations and the distribution found in
the plasma at baseline are listed in Additional file 4:
Table S3.
Data management
The ctDNA level was defined as the fraction of ctDNA
and expressed as the proportion of mutant alleles in the
total circulating cell-free DNA (mutated DNA/(mutated
DNA +wild-type DNA) and calculated by the Quanta-
soft software. The variation of the ctDNA level is re-
ported as a 95% confidence interval (95% CI) based on
Poisson statistics.
A substantial increase of the ctDNA level (HctDNA)
during the treatment course was defined as a value with
no overlap between the 95% CI of the current and im-
mediately preceding measurements.
Low ctDNA (LctDNA) after the first treatment cycle was
defined as a level with the lower 95% CI overlapping zero.
Statistical analysis
Full description is given in the Additional file 2: Supple-
mentary material.
Results
Between March 2010 and November 2015, 152 patients
were enrolled in the study. The patient flow is shown in
Fig. 1. One patient withdrew his consent and one suffered
from another malignant disease and was mistakenly en-
rolled leaving 150 patients for investigation. Analysis of
mutational status was not possible in 12 patients (8%) due
to limited access to tumor tissue or insufficient material in
the specimens. Thus data were available from 138 patients
(92%). Eighty-two patients (59%) had a tumor RAS/RAF
mutation and in 77 patients (94%) the mutation was found
in the plasma. Baseline patient characteristics of patients
with mutated DNA in plasma are shown in Table 1. There
was no statistically significant difference in terms of age,
gender, and tumor location between the group of patients
with wild-type DNA in the plasma and patients with mu-
tated DNA (data not shown). The 77 patients had at least
a baseline blood sample drawn and contributed with a
total of 571 analyzed blood samples. Twenty patients pro-
gressed on treatment (26%), one of which only had a
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baseline blood sample. Fifty-seven patients stopped treat-
ment without progressive disease (PD) (74%).
The time-of-progression plasma sample from patients
with a wild-type tumor was screened for RAS/RAF muta-
tions. All patients were plasma wild-type except one (1/21),
whose blood samples were not included in the analysis.
Effect of plasma mutational status
The median follow-up time was 35.3 months as estimated
by inverse Kaplan-Meier analysis. The overall survival
(OS) analysis was based on 114 events in the whole cohort
of 138 patients of which 124 had at least one response
evaluation. Based on tissue samples the best overall
response rate (partial response or complete response) was
29%, 18% and 59% in RAS mutated patients, BRAF mu-
tated patients, and wild type patients, respectively. In
plasma the same rates were 33%, 20% and 52%, respect-
ively. The difference in response rate between patients
with mutated DNA and wild type in plasma translated
into a significant difference in progression free survival
(PFS). The median PFS was 5.7 months (range 4.2–
7.0 months) and 7.8 months (range 6.9–9.9 months), re-
spectively, hazard ratio (HR) = 2.02, 95%CI = 1.38–2.95,
P < 0.001. A significant difference also applied to OS. The
median values were 12.7 months (range 10.2–16.0 months)
and 24.2 months (range 18.4–34.3 months), respectively,
HR = 2.50, 95%CI = 1.69–3.71, P < 0.001 (Fig. 2). Median
PFS was 6.2 months (range 4.4–7.2 months) and median
OS was 14.8 months (range 10.2–16.8 months) for plas-
matic RAS mutated patients alone (n = 67).
Effect of ctDNA level at baseline
Among the 77 patients with tumor and plasma mutation,
the ctDNA level at baseline ranged between 0.0026
and 80.43% of the total cell free DNA. The results in-
dicated a clear correlation between the ctDNA level as
divided according to the median value and PFS (HR = 3.95,
P = 0.017). Further calculation on the quantitative import-
ance of the ctDNA level was analyzed by logistic regression.
Increased ctDNA at baseline was clearly associated with an
increased risk of progression on treatment (relative risk
(RR) = 1.02, 95%CI = 1.01–1.03, P < 0.001).
Treatment related dynamics of ctDNA level
Figure 3 shows fluctuation of ctDNA level during the
treatment course up to nine cycles. It only includes
patients on treatment censored at discontinuation irre-
spective of reason. It is obvious that the ctDNA level de-
creases rapidly during the first three cycles of treatment
from around 20% at baseline to nadir values of approxi-
mately 3% before cycle four. The confidence intervals
during these and the few subsequent cycles were rather
narrow, but they widened towards the third evaluation
(pre-cycle nine). The reason was mainly a reduced num-
ber of patients for observation but also an increasing
Fig. 1 Flow chart
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fraction of progressing patients with a broad range of
ctDNA values.
The figure also shows an abrupt decrease of ctDNA
after start of treatment. LctDNA was found in 40% (27/
65) after the first cycle of chemotherapy (before cycle 2).
There was a strong correlation between LctDNA and
risk of progression during treatment. Only two patients
out of 27 (7%) progressed in the LctDNA group com-
pared to 17/38 (45%) in the other group (non-LctDNA)
(p = 0.001). This relationship is further underlined in the
analysis of PFS during treatment (Fig. 4). The difference
according to ctDNA status was statistically significant
(HR = 0.16, P = 0.017).
HctDNA at any point during the treatment course was
highly related to progression on treatment (RR = 4.58,
95%CI = 1.99–10.51, P < 0.001). A consecutive HctDNA
resulted in a similar high risk of progression (RR = 4.03,
95%CI = 2.11–7.70, P < 0.001). The increased level
appearing before progression was found by CT scan with
a median lead time of 51 days (range 14–133).
Discussion
In this prospective study of mCRC patients receiving
first line chemotherapy we observed a strong correlation
between the ctDNA level and clinical endpoints.
Chemotherapy is the corner stone in mCRC treatment.
Modern combinations of two or three drugs have improved
survival but the treatment still has severe limitations.
Firstly, it is only beneficial to two thirds of the patients and
secondly, it has serious toxicity. The current methods for
monitoring mCRC treatment are far from ideal. The only
Fig. 2 Overall survival according to mutational statusThe difference is statistically significant, HR = 2.50, 95%CI = 1.69–3.71, P < 0.001.Tick marks at
censor points.
Table 1 Baseline characteristics of patients with mutated DNA
in plasma (N = 77)
All patients with mutated
DNA in plasma
Parameter N (%)
Age, years
Median (range) 66 (35–79)
Gender
Female 29 (38)
Male 48 (62)
PS
0–1 73 (95)
2 4 (5)
Location of primary tumor
Right/transverse colon 25 (32)
Left colon 21 (27)
Rectum 31 (40)
Primary disseminated disease 63 (81)
Number of metastatic sites
≤ 2 53 (69)
> 2 24 (31)
Mutations in plasma DNA
KRAS 64 (83)
NRAS 3 (4)
BRAF 10 (13)
Abbreviations: N, number; PS, performance status. Some percentages do not
add up to 100% due to rounding
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recommended evaluation modality is imaging [17]. How-
ever, CT scanning has drawbacks as to tumor size and vol-
ume and is not applicable for small metastases (< 10 mm).
Furthermore, progression according to the RECIST criteria
calls for at least a 20% size increase.
Therefore, the identification of markers able to guide
the treatment holds high priority, especially biomarkers
allowing for discontinuation of ineffective treatment at an
early time. An indicator in the context of treatment effect
should be easily accessible for repeated measurement,
which in practice excludes tissue markers. Also, it requires
high specificity and sensitivity. Somatic tumor mutations
seem to be adequate for this purpose with ctDNA being
highly specific. The literature, however, is still sparse.
An approach based on ddPCR has high sensitivity and
seems to be in accordance with other techniques described
in the literature [18, 19]. It is also highly reproducible as
shown in our recent paper [20]. We here present results of
serial measurements over a whole treatment course in pa-
tients with RAS/RAF mutated tumors. Mutated DNA was
detected in the blood stream in > 90% of the patients. This
is in agreement with several other studies [21, 22].
Fig. 4 Progression free survivalPFS during treatment according to ctDNA at end of cycle one until end of treatment. The difference is statistically
significant, HR = 0.16, P = 0.017. Tick marks at censor points.
Fig. 3 Observed variation in fractional abundance (ctDNA level)ctDNA level is shown over the whole treatment course in all 77 patients with
plasma ctDNA.The figure gives mean value and 95%CI.
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We chose to investigate the clinical value of the frac-
tional abundance of ctDNA, since previous studies have
focused on this quantity as a central measure in the
prognostic and predictive setting [21, 23]. The interpret-
ation of ctDNA data in a clinical context calls for careful
consideration and at present there is no general agree-
ment as to quantitative classification related to clinical
parameters. Relative reduction of ctDNA level has limi-
tations, since it does not account for low baseline levels.
An absolute value in ng/ml or copies/ml seems more at-
tractive. We chose the 95% CI, which is a simple and
unique measure. It is easily calculated and seems rele-
vant to account for different values at different time
points over a long treatment course.
The prognostic value of ctDNA in mCRC patients has
previously been evaluated. Recent studies found a
marked prognostic value of ctDNA in OS estimates [24,
25]. Our result supports their conclusion, as patients
with a plasma mutation were shown to have a signifi-
cantly worse survival compared to the rest of the cohort
(Fig. 2). We also found that patients presenting with mu-
tated DNA in plasma had a lower response rate than
wild-type patients. This is in line with a recently con-
ducted study that found the same relation but only
based on the first radiologic assessment [21].
The present results indicate an influence of a high base-
line ctDNA level on treatment effect. With each increase
in baseline ctDNA level of 1%, the risk of treatment failure
increased by 2%. This suggests patients with a high ctDNA
level to have a poor prognosis, but a more detailed quanti-
fication of the threshold for effect is needed.
LctDNA correlated with a low risk of progression
under treatment (Fig. 4). Our findings confirm the re-
sults in a recent paper by Garlan et al. [24]. They re-
ported a low ctDNA level at baseline, or a level
decreasing below 0.1 ng/ml before cycle two, to indicate
long PFS and OS. Tie et al. reported that a reduction in
ctDNA level before cycle two correlated with response
at the first radiological evaluation and a trend for in-
creased PFS [21]. Our results showed agreement be-
tween reduction of ctDNA level and improved PFS, but
we did not find an association with response. The differ-
ence may be explained by different response rates. It was
52% in the study by Tie et al. and only 31% in the
present one. The lower rate may be due to RAS/RAF
mutations in all our patients.
The present results are the first to show the relation-
ship between increasing level of ctDNA and progression
over the whole treatment course. HctDNA at any time
implied a high risk of progression (RR = 4.58). The im-
portance of just one such increase was accentuated by
the fact that two consecutive HctDNA measurements
had a similar impact on the risk of progression (RR =
4.03). Hence, there does not seem to be evidence as to
postpone the change in treatment strategy until a second
increase is observed. On the other hand, a stable ctDNA
level encourages treatment continuation. The increase
appears with a lead time of approximately 2 months,
which is relevant in the clinical setting.
The present study has several limitations. First of all, it
only comprised patients with RAS/RAF mutated tumors,
which, however, applied to around 60% of the patients.
Additionally, the sample size of patients ending treat-
ment due to PD was small. The reasons for treatment
discontinuation, listed in the flow chart, are believed to
be in agreement with clinical practice. The correlations
of LctDNA with PFS and HctDNA with progression sug-
gest a predictive value of changes in ctDNA level, but a
randomized trial is needed for final proof.
Previous studies conclude that ctDNA is a more reliable
marker than carcinoembryonic antigen (CEA) which may
even be misleading [21, 26, 27]. Further, CEA is not part
of the ESMO guidelines [17] and consequently not in-
cluded in the present study. We only analyzed the plasma
samples from tumor wild-type patients at the time of pro-
gression, but it is not likely that patients without mutated
DNA at progression would have presented with mutated
DNA before start of treatment.
Conclusions
The present study adds preliminary evidence as to the
clinical relevance of ctDNA during treatment. An early
decrease holds promise as to a long progression free
interval. On the other hand a significant increase gives
notice of progression. Thus, ctDNA monitoring may be
a step towards precision medicine.
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